Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Graphite Bio, Inc. | CHIEF BUSINESS OFFICER | Common Stock | 300K | $1.22M | $4.08 | Apr 11, 2022 | Direct |
Avalo Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 4.72K | Sep 30, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
GRPH | Graphite Bio, Inc. | Apr 11, 2022 | 1 | $20.1K | 4 | Apr 13, 2022 | CHIEF BUSINESS OFFICER |
GRPH | Graphite Bio, Inc. | Feb 16, 2022 | 1 | $0 | 4 | Feb 18, 2022 | CHIEF BUSINESS OFFICER |
AVTX | Avalo Therapeutics, Inc. | Dec 1, 2021 | 0 | $0 | 4 | Dec 3, 2021 | Director |
AVTX | Avalo Therapeutics, Inc. | Sep 30, 2021 | 1 | $0 | 4 | Oct 4, 2021 | Director |
AVTX | Cerecor Inc. | Jun 30, 2021 | 1 | $0 | 4 | Jul 2, 2021 | Director |
GRPH | Graphite Bio, Inc. | Jun 24, 2021 | 0 | $0 | 3 | Jun 24, 2021 | CHIEF BUSINESS OFFICER |
AVTX | Cerecor Inc. | Jun 15, 2021 | 1 | $0 | 4 | Jun 17, 2021 | Director |
GRPH | Graphite Bio, Inc. | Jan 13, 2021 | 10 | $148K | 4 | Jul 1, 2021 | CHIEF BUSINESS OFFICER |